A Phase 3 interventional study of FAB122 in Amyotrophic Lateral Sclerosis, sponsored by Ferrer Internacional S.A.. Terminated at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by Ferrer Internacional S.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 27th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2023, is one of 22 in phase 3, and was the 43rd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Prilenia · Sites in Spain, United States, Belgium and 10 more countries
Ages 18–80
PhenoNet, Inc. · Sites in Spain, United States, Czechia and 3 more countries
Ages 18–75
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 24
First in 2007; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 51 interventional studies, 60 across the 5 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Ferrer Internacional S.A. is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Ferrer Internacional S.A. has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyotrophic Lateral Sclerosis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07414212Biogipuzkoa Health Research InstituteEvaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-25 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
a female subject should not be able to become pregnant up to 30 days after the last dose of FAB122 and needs to meet at least one of the following criteria:
a male patient must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FAB122 Daily dose 100 mg Data presented for the FAB122 study group correspond to subjects receiving FAB122 in the ADORE study as well as the ADOREXT study (FAB122-FAB122).
Drug: FAB122
Drug: FAB122 Daily dose 100 mg Data presented for the placebo study group correspond to subjects receiving placebo in the ADORE study and FAB122in the ADOREXT study (placebo-FAB122).
Drug: FAB122
FAB122 Daily dose 100 mg
Number of Participants Experiencing Treatment Emergent Adverse Events
To evaluate the long-term safety of FAB122 in patients with ALS by assessing Number of Participants experiencing Treatment Emergent Adverse Events, evaluating nature and severity. The study duration for these subjects, and therefore the duration of FAB122 treatment, was variable depending on the subject's start date, ranging from 3 to approximately 44 weeks.
Time frame: approximately 44 weeks
The Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study
Change from baseline in ALSFRS-R total score until the end of the study. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome.
Time frame: 45 weeks
| Milestone | FAB122 | Placebo |
|---|---|---|
| Started | 135 | 66 |
| Completed | 110 | 54 |
| Not completed | 25 | 12 |
| Withdrew: Death | 16 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 |
| Withdrew: Disease progression | 1 | 0 |
| Withdrew: Other causes | 2 | 1 |
To evaluate the long-term safety of FAB122 in patients with ALS by assessing Number of Participants experiencing Treatment Emergent Adverse Events, evaluating nature and severity. The study duration for these subjects, and therefore the duration of FAB122 treatment, was variable depending on the subject's start date, ranging from 3 to approximately 44 weeks.
| Participants | FAB122 | Placebo |
|---|---|---|
| Any TEAE | 77 | 41 |
| Any Serious AE | 29 | 15 |
| Any Serious TEAE | 29 | 15 |
| Any TEAE leading to treatment discontinuation | 7 | 5 |
| Any AE leading to death | 16 | 9 |
| TEAE by relationship - Unrelated | 75 | 40 |
| TEAE by relationship - Related | 6 | 3 |
| TEAE by Severity - Mild | 52 | 31 |
| TEAE by Severity - Moderate | 32 | 17 |
| TEAE by Severity - Severe | 24 | 10 |
Change from baseline in ALSFRS-R total score until the end of the study. Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), Maximum value is 48 points and represents better outcome. Minimum value is 0 and represents worse outcome.
| units on a scale | FAB122 | Placebo |
|---|---|---|
| The Secondary Efficacy Objective to Evaluate the Effect of Treatment With FAB122 Based on Change From Baseline in ALSFRS-R Until End of Study | -4.4 ± 4.8 | -3.8 ± 5 |
Collected over 45 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FAB122 | 16/135 (11.9%) | 29/135 (21.5%) | 77/135 (57%) |
| Placebo | 9/66 (13.6%) | 15/66 (22.7%) | 41/66 (62.1%) |
| Event | FAB122 | Placebo |
|---|---|---|
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 10/135 | 4/66 |
| DysponeaRespiratory, thoracic and mediastinal disorders | 2/135 | 2/66 |
| DeathGeneral disorders | 0/135 | 2/66 |
| PneumoniaInfections and infestations | 4/135 | 1/66 |
| Chronic respiratory failureRespiratory, thoracic and mediastinal disorders | 2/135 | 1/66 |
| Pneumonia aspirationInfections and infestations | 2/135 | 1/66 |
| COVID-19Infections and infestations | 1/135 | 1/66 |
| Lower respiratory track infectionInfections and infestations | 0/135 | 1/66 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/135 | 1/66 |
| Amyotrophic Lateral SclerosisNervous system disorders | 0/135 | 1/66 |
| Event | FAB122 | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 5/135 | 6/66 |
| Urinary track infectiousInfections and infestations | 11/135 | 1/66 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 11/135 | 4/66 |
| DysphagiaGastrointestinal disorders | 7/135 | 3/66 |
| DiarrhoeaGastrointestinal disorders | 1/135 | 3/66 |
| Renal ColicRenal and urinary disorders | 1/135 | 3/66 |
| PneumoniaInfections and infestations | 6/135 | 1/66 |
| Upper respiratory tract infectionInfections and infestations | 3/135 | 2/66 |
| InfluenzaInfections and infestations | 0/135 | 2/66 |
| Lower respiratory track infectionInfections and infestations | 0/135 | 2/66 |
Data presented for the FAB122 study group correspond to subjects receiving FAB122 in the ADORE study as well as in the ADOREXT study (FAB122-FAB122). Data presented for the Placebo study group correspond to subjects receiving Placebo in the ADORE study and FAB122 in the ADOREXT study (Placebo-FAB122).
| Age, Customized(years) | FAB122 | Placebo | Total |
|---|---|---|---|
| Mean (SD) | 58.4 ± 10.6 | 58.5 ± 10.5 | 58.5 ± 10.5 |
| Sex: Female, Male(Participants) | FAB122 | Placebo | Total |
|---|---|---|---|
| Female | 57 | 30 | 87 |
| Male | 78 | 36 | 114 |
| Ethnicity (NIH/OMB)(Participants) | FAB122 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 28 | 16 | 44 |
| Not Hispanic or Latino | 94 | 48 | 142 |
| Unknown or Not Reported | 13 | 2 | 15 |
| Race (NIH/OMB)(Participants) | FAB122 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 119 | 63 | 182 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 15 | 3 | 18 |
| Region of Enrollment(participants) | FAB122 | Placebo | Total |
|---|---|---|---|
| Europe | 135 | 66 | 201 |
| BMI(kg/m^2) | FAB122 | Placebo | Total |
|---|---|---|---|
| Mean | 25.64 ± 4.03 | 24.76 ± 3.23 | 25.35 ± 3.8 |
| Weight(KG) | FAB122 | Placebo | Total |
|---|---|---|---|
| Mean | 74.87 ± 14.83 | 71.07 ± 13.32 | 73.62 ± 14.43 |
| Height(CM) | FAB122 | Placebo | Total |
|---|---|---|---|
| Mean | 170.5 ± 9.5 | 169 ± 9.8 | 170 ± 9.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2023 to primary completion in Jan 2024, 10 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →